Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

Mr_Charlie Apr. 17 at 2:05 PM

$PDSB 7 days above water, we are getting there. I just don't know where? We need a partnership.

0 · Reply

Locke1 Apr. 17 at 7:35 AM

$PDSB stock is up 100% and people freaking out. hilarious.

1 · Reply

jimmythefish Apr. 16 at 6:37 PM

$PDSB for info For the 2026 ASCO Annual Meeting (May 29–June 2), abstract titles will be released on April 21, 2026, with the majority of abstracts released on May 21, 2026, at 5:00 PM (ET). Late-breaking abstracts (LBAs) will be available later,

0 · Reply

BigPug Apr. 16 at 6:15 PM

$PDSB https://ascopubs.org/doi/10.1200/OA-25-00173

0 · Reply

MQuick Apr. 16 at 5:23 PM

$PDSB she breaks $1.50 today

1 · Reply

AyR15 Apr. 16 at 5:22 PM

$PDSB v shaped recovery would be very strong. Pretty solid volume, I think a lot of continued buying today. Some profit taking mixed in for sure after 100% run

0 · Reply

Test2025 Apr. 16 at 4:15 PM

$PDSB company it self is dumping shares? Doesn't want to stay above 1 to meet compliance?

0 · Reply

Mr_Charlie Apr. 16 at 4:14 PM

$PDSB panic sale.

1 · Reply

rwol9999 Apr. 16 at 3:49 PM

$PDSB Y all still cant have my shares!!!!!!!! I am in for another 2 years!!!

0 · Reply

HoHoHoHum Apr. 16 at 3:36 PM

$PDSB i suppose this profit taking is inevitable. i hope we stay above 1 for another 5 trading days.

0 · Reply

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

Mar 30, 2026, 7:00 AM EDT - 18 days ago

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

Mar 24, 2026, 4:05 PM EDT - 23 days ago

PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

Feb 20, 2026, 8:30 AM EST - 2 months ago

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

Jan 28, 2026, 8:45 AM EST - 2 months ago

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Jan 22, 2026, 8:45 AM EST - 3 months ago

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

Jan 9, 2026, 8:45 AM EST - 3 months ago

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

Dec 9, 2025, 8:00 AM EST - 4 months ago

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Dec 2, 2025, 8:30 AM EST - 4 months ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Nov 13, 2025, 7:30 AM EST - 5 months ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 5 months ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 5 months ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 5 months ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 6 months ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 6 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 7 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 8 months ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 8:30 AM EDT - 8 months ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 7:00 AM EDT - 8 months ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 9, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 22, 2025, 5:26 PM EDT - 11 months ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2025, 8:00 AM EDT - 11 months ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 1 year ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 1 year ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 1 year ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 1 year ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 9, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

Aug 1, 2024, 7:45 AM EDT - 1 year ago

PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer

Jul 31, 2024, 4:01 PM EDT - 1 year ago

PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time

Mr_Charlie Apr. 17 at 2:05 PM

$PDSB 7 days above water, we are getting there. I just don't know where? We need a partnership.

0 · Reply

Locke1 Apr. 17 at 7:35 AM

$PDSB stock is up 100% and people freaking out. hilarious.

1 · Reply

jimmythefish Apr. 16 at 6:37 PM

0 · Reply

BigPug Apr. 16 at 6:15 PM

$PDSB https://ascopubs.org/doi/10.1200/OA-25-00173

0 · Reply

MQuick Apr. 16 at 5:23 PM

$PDSB she breaks $1.50 today

1 · Reply

AyR15 Apr. 16 at 5:22 PM

$PDSB v shaped recovery would be very strong. Pretty solid volume, I think a lot of continued buying today. Some profit taking mixed in for sure after 100% run

0 · Reply

Test2025 Apr. 16 at 4:15 PM

$PDSB company it self is dumping shares? Doesn't want to stay above 1 to meet compliance?

0 · Reply

Mr_Charlie Apr. 16 at 4:14 PM

$PDSB panic sale.

1 · Reply

rwol9999 Apr. 16 at 3:49 PM

$PDSB Y all still cant have my shares!!!!!!!! I am in for another 2 years!!!

0 · Reply

HoHoHoHum Apr. 16 at 3:36 PM

$PDSB i suppose this profit taking is inevitable. i hope we stay above 1 for another 5 trading days.

0 · Reply

Raven5059 Apr. 16 at 3:00 PM

$PDSB full article explaining yesterday's jump. The pull back today is to be expected. I'm guessing more than a few retails are jumping ship right now. https://ascopubs.org/doi/10.1200/OA-25-00173

0 · Reply

AyR15 Apr. 16 at 2:23 PM

$PDSB need a bounce off 1.20 or may get gross

0 · Reply

Mr_Charlie Apr. 16 at 1:49 PM

$PDSB the expected drop. News yesterday day were good, but not as good as many people think. Partnership is key here. Trials with 9 patients have little impact.

1 · Reply

Ontherag Apr. 16 at 12:35 PM

$PDSB

0 · Reply

wyoming2020 Apr. 16 at 12:34 PM

$PDSB still here

0 · Reply

dvice2 Apr. 16 at 12:03 PM

$PDSB ASCO titles next Tuesday 🤞

0 · Reply

MQuick Apr. 16 at 11:26 AM

$PDSB time for a legit partnership

0 · Reply

SadyK189 Apr. 16 at 2:44 AM

Top Stocks to watch tomorrow 2 / 2: $XNDU $SKLZ $MNTS $TSHA $PDSB XNDU: Looking good on daily chart. Key support at 19 - 21.50. Next key level to test 31 - 34. Currently at 27.50 MNTS: Alerted at 5.56. Currently at 6.95. Key support at 5.40 - 5.80. Next key level to test is 7.8 - 8.2. SKLZ: Looking good on 4hours chart. 3.35 - 3.60 is acting as key support zone. Next key level to test 5.20 - 5.50. Currently at 4.52 TSHA: Good close of daily candle. Key support at 4.8 - 5.15. Next key level to test 6.75 - 7.10. Currently at 5.90 PDSB is trendingly nicely on daily chart. Key support at 0.98 - 1.10. Next key level to test 1.65 - 1.75. Currently at 1.39.

0 · Reply

imraven Apr. 15 at 11:29 PM

$PDSB I am out for now. GL all.

2 · Reply

KG1816 Apr. 15 at 10:32 PM

$PDSB 🌹

0 · Reply

MQuick Apr. 15 at 9:14 PM

$PDSB gap to fill at $2.80

1 · Reply

Market Cap	75.91M
Revenue (ttm)	0.00
Net Income (ttm)	-34.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.27

Volume	1,710,600
Avg Vol	675,302
Day's Range	N/A - N/A
Shares Out	55.82M
Stochastic %K	84%
Beta	1.20
Analysts	Strong Sell
Price Target	$7.50